NCT05631262View on ClinicalTrials.gov

SKB264 Monotherapy in Selected Subjects with Advanced Solid Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Selected Subjects with Advanced Solid Tumors
Interventions
DRUG

SKB264

Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy

DRUG

Docetaxel

Part II Control group will receive docetaxel monotherapy.

Trial Locations (1)

Unknown

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY